FDA Requests Information on Design and Safety Considerations for Ibogaine Clinical Trials

Summary

The US Food and Drug Administration (FDA) is seeking public input on its approach to designing early-phase clinical trials for ibogaine-based medications, as part of its efforts to ensure the safety and efficacy of these treatments.